Your legacy can help bring an end to CMT. Learn how a planned gift can make an impact for generations to come.
For Researchers & Industry
CMTAWinter2021Report
CMTA’s $240K Investment Targets Gene Replacement Therapy in CMT4 Subtypes
…the Strategy to Accelerate Research (STAR) initiative, CMTA has been at the forefront of accelerating gene replacement therapies for CMT, underscoring our leadership in this critical area of research,” said…
CMTA’s $450K Investment Targets New Approach to Treatment for Patients with CMT1A and CMT1B
The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth (CMT) disease research aimed at bringing treatments to patients, announced today an investment of $450K into a new scientific approach…
A Comprehensive Guide to Clinical Trials
As the CMTA’s $23.5 million investment in research begins to return dividends, more and more potential treatments are advancing to the clinical trial stage. Here’s a quick guide to clinical…
CMTA Adds Drug Development Expert Martine Garnier to STAR Advisory Board
…disease. It does so with an aggressive, multipronged attack, bringing together a group of top-flight researchers and experts and directly funding their work. CMTA launched its Strategy to Accelerate Research,…
Seattle Focus Group with Acceleron Pharma
We are pleased to announce another opportunity to get involved with the CMTA’s Patients as Partners in Research initiative! The goal of Patients as Partners in Research is to advance…